CrowYJ, LebonP, CasanovaJL, GresserI. 2018. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. J Clin Immunol, 38(6):694–698.
2.
DupuisS, JouanguyE, Al-HajjarS, FieschiC, Al-MohsenIZ, Al-JumaahS, YangK, ChapgierA, EidenschenkC, EidP, Al GhonaiumA, TufenkejiH, FrayhaH, Al-GazlanS, Al-RayesH, SchreiberRD, GresserI, CasanovaJL. 2003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet, 33(3):388–391.
3.
GresserI. 1987a. A. Chekhov, M.D., and Coley's toxins. N Engl J Med, 317(7):457.
4.
GresserI. 1987b. The man who studied interferon without really trying. J Interferon Res, 7(5):445–449.
HallerO, ArnheiterH, LindenmannJ, GresserI. 1980. Host gene influences sensitivity to interferon action selectively for influenza virus. Nature, 283(5748):660–662.
11.
IsaacsA, LindenmannJ. 1957. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci, 147(927):258–267.
12.
LebonP, CrowYJ, CasanovaJL, GresserI. 2019. [Pathological consequences of excess of interferon in vivo]. Med Sci (Paris), 35(3):232–235.
13.
LebonP, Pitha-RowePM. 2013. Life devoted to viruses and interferon: Charles Chany (1920–2013). J Interferon Cytokine Res, 33(10):549–550.
14.
NathanCF, MurrayHW, WiebeME, RubinBY. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med, 158(3):670–689.
15.
StarkGR, DarnellJEJr. 2012. The JAK-STAT pathway at twenty. Immunity, 36(4):503–514.
16.
UzéG, LutfallaG, GresserI. 1990. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell, 60(2):225–234.
